Home EDIT
10.25
  Price1.89%   +0.19
 
loading

Editas Medicine (EDIT) Latest News

Dec-02-22 11:31AM Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research
Dec-01-22 04:01AM Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell DiseaseGlobeNewswire Inc.
Nov-28-22 01:08AM Editas (EDIT) Declines More Than 30% in 3 Months: Here's WhyZacks Investment Research
Nov-23-22 09:55AM Here's Why Editas (EDIT) Looks Ripe for Bottom FishingZacks Investment Research
Nov-20-22 08:30AM Where Will Editas Medicine Be in 1 Year?The Motley Fool
Nov-18-22 02:51AM Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina TreatmentBenzinga
11:58AM Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022Benzinga
Nov-18-22 09:51AM Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock DownZacks Investment Research
09:29AM Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & PayneBenzinga
Nov-18-22 07:57AM Intuit To $490? Here Are 5 Other Price Target Changes For FridayBenzinga
06:32AM Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%Benzinga
Nov-18-22 05:14AM Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From YesterdayBenzinga
Nov-17-22 04:11AM Why Editas Medicine's Shares Are Falling ThursdayThe Motley Fool
02:32AM Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 EarningsBenzinga
Nov-17-22 01:20AM Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day SessionBenzinga
12:07PM S&P 500 Down 1%; Crude Oil Drops SharplyBenzinga
Nov-17-22 11:30AM BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On ThursdayBenzinga
07:15AM Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE TrialGlobeNewswire Inc.
Nov-03-22 02:16AM What 5 Analyst Ratings Have To Say About Editas MedicineBenzinga
01:11AM Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in FocusZacks Investment Research
Nov-02-22 06:30AM Editas Medicine Announces Third Quarter 2022 Results and Business UpdatesGlobeNewswire Inc.
Nov-01-22 01:13AM Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
12:28PM BioNTech (BNTX) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
Oct-31-22 12:48PM Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
11:49AM Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?Zacks Investment Research
Oct-31-22 09:55AM Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to TradeZacks Investment Research
Oct-28-22 08:50AM Zacks Earnings ESP: A Better Way to Find Earnings Surprises for MedicalZacks Investment Research
Oct-27-22 02:03AM Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
01:08AM Incyte (INCY) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
Oct-27-22 11:09AM AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?Zacks Investment Research
10:03AM Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to DeclineZacks Investment Research
Oct-26-22 04:16AM Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?Zacks Investment Research
12:06PM Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
Oct-26-22 12:01PM Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
06:30AM Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate UpdateGlobeNewswire Inc.
Oct-25-22 12:53PM CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
12:39PM What's in Store for Gilead (GILD) This Earnings Season?Zacks Investment Research
Oct-24-22 08:50AM Zacks Earnings ESP: A Better Way to Find Earnings Surprises for MedicalZacks Investment Research
07:55AM Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?Zacks Investment Research
Oct-19-22 03:10AM Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 UpdateSeeking Alpha
Oct-13-22 06:00AM Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual MeetingGlobeNewswire Inc.
Oct-06-22 08:45AM The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam TherapeuticsZacks Investment Research
Oct-05-22 09:18AM 4 Biotechs to Watch Amid Rising Prominence of Gene TherapiesZacks Investment Research
Sep-29-22 10:06AM Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022Benzinga
Sep-02-22 11:32AM Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?Zacks Investment Research
Sep-01-22 06:30AM Editas Medicine to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.
Aug-19-22 09:55AM Editas (EDIT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research
Aug-18-22 08:46AM GSK NDA for Myelofibrosis Candidate Gets FDA AcceptanceZacks Investment Research
Aug-16-22 09:55AM Does Editas (EDIT) Have the Potential to Rally 65% as Wall Street Analysts Expect?Zacks Investment Research
Aug-04-22 12:30PM Editas' (EDIT) Loss Narrows in Q2, Revenues Trump EstimatesZacks Investment Research
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:    |  Volume (24h):